Korean J Pediatr Infect Dis.  2011 Jun;18(1):97-102.

Four Children with Multidrug-resistant Acinetobactor baumanii Infections in the Intensive Care Units of a University Hospital

• Lee KS
• Lee GM
• Yoon HS
• Chung SJ
• Cha SH
• Chun HK

Abstract

The Multidrug-resistant Acinetobactor baumanii (MDRAB) is an opportunistic pathogen. Patients with long periods of hospital stay and/or under intensive care unit (ICU) receiving invasive management are more susceptible to this pathogen. In this report, four children with MDRAB infection are reviewed and described their clinical characteristics. There had been concurrent outbreaks of MDRAB infection in adult patients in the ICU at this period of time. The first child had received a craniotomy and epidural hematoma evacuation. The second child was admitted for status epilepticus with hydrocephalus. The third child had pneumonia with status epilepticus with hydrocephalus. The fourth child had poor activity due to hypoxic ischemic encephalopathy and convulsive disorder. Except the fourth child, all had not been exposed to carbapenem prior to infection of MDRAB. That imply the cause of MDRAB infections may be associated with invasive management and prolonged hospitalization together with the previous exposure to carbapenem in our cases. We would like to emphasize the importance and minimizing the spread of hospital infection in patients under prolonged intensive care management regardless of the use of carbapenem.

Keyword

Multidrug-resistant Acinetobactor baumanii (MDRAB); Hospital infection; Outbreak

MeSH Terms

Adult
Child
Craniotomy
Cross Infection
Disease Outbreaks
Hematoma
Hospitalization
Humans
Hydrocephalus
Hypoxia-Ischemia, Brain
Critical Care
Intensive Care Units
Length of Stay
Pneumonia
Status Epilepticus

Reference

1. Fulnecky EJ, Wright D, Scheld M, Kanawati L, Shoham S. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J Infect. 2005. 51:e249–e251.

2. Chang PY, Hsueh PR, Wu PS, Chan PC, Yang TT, Lu CY, et al. Multidrug-resistant Acinetobacter baumannii isolates in pediatric patients of a university hospital in Taiwan. J Microbiol Immunol Infect. 2007. 40:406–410.

3. Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-buisson C, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic methods. J Clin Microbiol. 1994. 32:2677–2681.

4. Moon SM, Son JS, Lee HJ, Chun HK, Kim ML, Lee MS. The analysis of risk factor and infection control of carbapenem-resistant Acinetobacter baumannii in a medical intensive care unit. Korean J Nosocomial Infect Control. 2009. 14:72–78.

5. Yang HY, Lee HJ, Suh JT, Lee KM. Outbreaks of imipenem resistant Acinetobacter baumannii producing OXA-23 beta-lactamase in a tertiary care hospital in Korea. Yonsei Med J. 2009. 50:764–770.

6. López-Hernández S, Alarcón T, López-Brea M. Carbapenem Resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain. Eur J Clin Microbiol Infect Dis. 1998. 17:282–285.

7. Go ES, Urban C, Janice B, Kreiswirth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polimyxin B and sulbactam. Lancet. 1994. 344:1329–1332.

8. Paton R, Miles RS, Hood J, Amyes SGB. ARI-1/beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents. 1993. 2:81–88.

9. Cisneros JM, Rodríguez-Baño J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect. 2002. 8:687–693.

10. Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, et al. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis. 2008. 62:67–80.

11. Patzer JA, Dzierzanowska D, Turner PJ. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007). J Antimicrob Chemother. 2008. 62:369–375.

12. Hogg GM, Barr JG, Webb CH. In-vitro activity of the combination of colistin and rifampicin againts multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother. 1998. 41:494–495.